Vistagen Therapeutics Files 8-K on Shareholder Vote Matters

TL;DR

VTGN filed an 8-K on shareholder vote matters, check for updates on corporate actions.

AI Summary

Vistagen Therapeutics, Inc. filed an 8-K on May 31, 2024, reporting on matters submitted to a vote of security holders as of May 29, 2024. The filing details the company's corporate structure and operational information, including its principal executive offices located at 343 Allerton Ave., South San Francisco, California.

Why It Matters

This filing provides an update on corporate governance and shareholder decisions, which can impact investor confidence and the company's strategic direction.

Risk Assessment

Risk Level: low — The filing is procedural and reports on standard corporate matters without disclosing new financial or operational risks.

Key Players & Entities

• Vistagen Therapeutics, Inc. (company) — Registrant
• May 29, 2024 (date) — Earliest event reported
• May 31, 2024 (date) — Date of report
• 343 Allerton Ave., South San Francisco, California (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock , par value $0.001 per share VTGN Nasdaq Capital Market

Filing Documents

• vtgn20240529_8k.htm (8-K) — 32KB
• 0001437749-24-018902.txt ( ) — 161KB
• vtgn-20240529.xsd (EX-101.SCH) — 3KB
• vtgn-20240529_def.xml (EX-101.DEF) — 11KB
• vtgn-20240529_lab.xml (EX-101.LAB) — 15KB
• vtgn-20240529_pre.xml (EX-101.PRE) — 11KB
• vtgn20240529_8k_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders On May 29, 2024, Vistagen Therapeutics, Inc. (the " Company ") held a special meeting of stockholders (the " Special Meeting "). As set forth below, the Company's stockholders approved the two matters voted upon at the Special Meeting: (i) an amendment to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan (the " 2019 Plan "); and (ii) an amendment to the Company's 2019 Employee Stock Purchase Plan (" 2019 ESPP "). The matters voted upon at the Special Meeting and the results of the voting at the Special Meeting are as follows: Proposal No. 1 – Amendment to the Vistagen Therapeutics, Inc. Amended and Restated 2019 Omnibus Equity Incentive Plan For Against Abstain Number of Votes Cast 12,731,981 730,584 2,072,262 Percentage (%) of Votes Received 82.0% 4.7% 13.3% The vote required to approve an amendment to the 2019 Plan (the " 2019 Plan Amendment "), which 2019 Plan Amendment increases the number of shares of the Company's common stock, par value $0.001 per share (" Common Stock "), authorized for issuance thereunder from 1,000,000 shares to 5,000,000 shares, was the affirmative vote of a majority of the votes cast on the proposal. Accordingly, the Company's stockholders duly approved the 2019 Plan Amendment. Proposal No.2 – Amendment to the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan For Against Abstain Number of Votes Cast 12,788,811 670,714 2,075,302 Percentage (%) of Votes Received 82.3% 4.3% 13.4% The vote required to approve an amendment to the 2019 ESPP (the " 2019 ESP P Amendment "), which 2019 ESPP Amendment increases the number of shares of the Company's Common Stock authorized for issuance thereunder from 33,334 shares to 1,000,000 shares, was the affirmative vote of a majority of the votes cast on the proposal. Accordingly, the Company's stockholders duly approved the 2019 ESPP Amendment. For more information

Signatures

Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: May 31, 2024 By: /s/ Shawn K. Singh Shawn K. Singh, JD Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR